Although immune checkpoints inhibitors have exhibited promising activity in clinical trials in
non-small cell lung cancer (NSCLC) patients, the current programmed cell death-ligand 1 …

Immune checkpoint inhibitor (ICI) therapies, including the programmed cell death protein 1
(PD-1) axis blockade, are considered a major oncological breakthrough of the early twenty …

In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors …

Introduction Programmed death ligand 1 (PD-L1) testing of non–small cell lung cancer
(NSCLC) specimens helps select patients most likely to respond to immune checkpoint …

The recent discovery of immune checkpoints inhibitors, especially anti-programmed cell
death protein 1 (PD-1) and anti-programmed cell death protein ligand 1 (PD-L1) monoclonal …

Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially
increase the efficacy of therapy for various malignancies, including non–small cell lung …

Checkpoint inhibitors targeting the PD-1/PD-L1 axis are a promising treatment option in
several tumor types. PD-L1 expression detected by immunohistochemistry is the first …

The emergence of immunotherapy has dramatically changed how non–small cell lung
cancer is treated, and longer survival is now possible for some patients, even those with …

Immune checkpoint blockade therapy by targeting the programmed death protein
1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical …

Therapies targeting immune checkpoints have recently shown encouraging activity in
patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) …